A similar kinome adaptive response has been observed in KRAS G12C-mutant tumor cells using irreversible cysteine reactive KRAS G12 inhibitors (47, 48, 49), which specifically interact with the mutant cysteine on the 12th residue of KRAS to inactivate the kinase activity (50). The gene discussed is KRAS; the disease is neoplasm.